Last Updated Nov 14, 2025
Overview
Chekable provides a generative Artificial Intelligence (AI) platform to help patent professionals streamline drafting, reducing time-consuming mechanical work. While it lacks a dedicated mobile app, the software’s USPTO-compliant and ‘zero hallucination’ engine is a compelling tool for improving client outcomes and practice efficiency.
Be the first one to leave a review!
No review found
Starting Price
Custom
What Is Chekable?
Chekable is a generative AI platform built specifically for patent attorneys, agents, and IP teams. It streamlines the end-to-end patent filing process by automating mechanical drafting and complex searches. The software uses agentic AI pipelines to help practitioners draft provisional and non-provisional applications, convert existing documents, and perform semantic prior art searches, significantly reducing drafting time. This allows patent professionals to focus on high-value strategic work rather than repetitive tasks.
Chekable Pricing
The Chekable pricing is based on the specific needs of your practice. A free trial is available to test the platform.
Chekable Integrations
Who Is Chekable For?
Chekable is ideal for a wide range of professionals across the legal sector, including:
- Patent attorneys
- Patent agents
- Solo practitioners (IP)
- Boutique IP firms
- In-house corporate IP teams
Is Chekable Right For You?
Chekable is designed for patent professionals who want to integrate specialized AI into their drafting workflow while maintaining full control and compliance. Its standout capability is its ‘agentic AI’, which iteratively drafts applications and checks for errors, positioning itself as a high-diligence assistant. The platform is an official partner of the National Association of Patent Practitioners (NAPP) and a graduate of the NEC X venture studio, signaling strong industry validation for its focused, AI-driven approach.
Are you still not sure about Chekable and need expert advice to make an informed decision? Reach out to us at (661) 384-7070 now.